The THRIVE Initiative: The Increasing Role of Targeted Biologics in Moderate-to-Severe Psoriasis

View Activity

FACULTY

Joel Gelfand, MD, MSCE
Professor of Dermatology and Epidemiology
Vice Chair for Clinical Research
Medical Director, Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

PROGRAM OVERVIEW

This case-based enduring activity will cover the long-term treatment and management of patients with psoriasis.

TARGET AUDIENCE

This activity is intended for dermatologists, physician assistants, nurses and nurse practitioners who are involved in the management of patients with psoriasis.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Review the molecular causes of psoriasis, as well as treatments that target these pathophysiologic mechanisms
  • Describe why psoriasis and cardiovascular disease are related, and the implications for CVD screening and management in patients with psoriasis
  • Review the mechanisms of action and efficacy/safety data of new and investigational biologics for patients with moderate to severe psoriasis
  • Assess ways in which to improve communication with psoriasis patients in order to maintain adherence and improve quality of life

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the long-term treatment and management of patients with psoriasis.

CNE Credits:
1.0 ANCC Contact Hour

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTERESTS

Joel M. Gelfand, MD: In the past 12 months, Dr. Gelfand served as a consultant for and received honoraria from BMS, Boehringer Ingelheim, Janssen Biologics, Novartis Corp, UCB (DSMB), Sanofi, and Pfizer Inc. He has received research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Boehringer Ingelheim, Janssen, Novartis Corp, Celgene, Ortho Dermatologics, and Pfizer Inc. and has received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly, Ortho Dermatologics, and Novartis. Dr. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T cell lymphoma. Dr. Gelfand is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology.

CME Content Review
The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Chris Drury, Medical and Scientific Services for Med Learning Group, has nothing to disclose.
Melissa Johnson, Sr. Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, Dr. Gelfand may mention the use of medications for both FDA-approved and non-approved indications

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this live activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the live activity.
3. Complete pre-and-post survey.
4. Submit the evaluation form online.
You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: November 22, 2019

EXPIRATION DATE: November 22, 2020

View Activity

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.